Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Carolyn Tang Biography and Net Worth

General Counsel of Arcus Biosciences

The estimated Net Worth of Carolyn C. Tang is at least $834 Thousand dollars as of 16 December 2021. Carolyn Tang owns over 1,109 units of Arcus Biosciences Inc stock worth over $719,773 and over the last few years Carolyn sold RCUS stock worth over $114,132.

Carolyn has made over 2 trades of the Arcus Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Carolyn sold 1,109 units of RCUS stock worth $44,493 on 16 December 2021.

The largest trade Carolyn's ever made was selling 2,915 units of Arcus Biosciences Inc stock on 16 June 2021 worth over $69,639. On average, Carolyn trades about 1,341 units every 61 days since 2021. As of 16 December 2021 Carolyn still owns at least 17,564 units of Arcus Biosciences Inc stock.

What is Carolyn C. Tang's net worth?: The estimated net worth of Carolyn C. Tang is at least $458,487.36 as of December 16th, 2022. Ms. Tang owns 28,584 shares of Arcus Biosciences stock worth more than $458,487 as of November 14th. This net worth evaluation does not reflect any other assets that Ms. Tang may own. Learn More about Carolyn C. Tang's net worth.
How do I contact Carolyn C. Tang?: The corporate mailing address for Ms. Tang and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at [email protected]. Learn More on Carolyn C. Tang's contact information.
Has Carolyn C. Tang been buying or selling shares of Arcus Biosciences?: Carolyn C. Tang has not been actively trading shares of Arcus Biosciences within the last three months. Most recently, Carolyn C. Tang sold 2,523 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $30.75, for a transaction totalling $77,582.25. Following the completion of the sale, the general counsel now directly owns 28,584 shares of the company's stock, valued at $878,958. Learn More on Carolyn C. Tang's trading history.
Who are Arcus Biosciences' active insiders?: Arcus Biosciences' insider roster includes Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.
Are insiders buying or selling shares of Arcus Biosciences?: During the last twelve months, Arcus Biosciences insiders bought shares 1 times. They purchased a total of 15,238,095 shares worth more than $319,999,995.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 83,955 shares worth more than $1,577,199.69. The most recent insider tranaction occured on March, 27th when COO Jennifer Jarrett sold 11,551 shares worth more than $202,720.05. Insiders at Arcus Biosciences own 12.3% of the company. Learn More about insider trades at Arcus Biosciences.
Information on this page was last updated on 3/27/2024.

Carolyn C. Tang Insider Trading History at Arcus Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2022	Sell	2,523	$30.75	$77,582.25	28,584
6/16/2022	Sell	1,400	$20.72	$29,008.00	25,431
12/16/2021	Sell	487	$39.82	$19,392.34
6/16/2021	Sell	1,309	$24.16	$31,625.44

Carolyn C. Tang Buying and Selling Activity at Arcus Biosciences

Arcus Biosciences Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Today's Range

Now: $16.04

$15.83

$16.48

50 Day Range

MA: $16.63

$15.28

$18.44

2 Week Range

Now: $16.04

$13.49

$20.31

Volume

39,307 shs

Average Volume

732,875 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Central Bank Abandons USD

From True Gold Republic | Ad

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.